AR109103A1 - Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert - Google Patents
Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ertInfo
- Publication number
- AR109103A1 AR109103A1 ARP170102027A ARP170102027A AR109103A1 AR 109103 A1 AR109103 A1 AR 109103A1 AR P170102027 A ARP170102027 A AR P170102027A AR P170102027 A ARP170102027 A AR P170102027A AR 109103 A1 AR109103 A1 AR 109103A1
- Authority
- AR
- Argentina
- Prior art keywords
- treated
- fabry
- ert
- treatment
- disease
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 3
- 239000012458 free base Substances 0.000 abstract 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 2
- 229950007469 migalastat Drugs 0.000 abstract 2
- 230000002861 ventricular Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000557 podocyte Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Se proveen regímenes de dosificación para el tratamiento de la enfermedad de Fabry en un paciente. Algunos métodos se relacionan con el tratamiento de pacientes con Fabry no tratados previamente (naïve) o tratados con ERT (terapia de reemplazo enzimático). Algunos métodos comprenden administrar al paciente aproximadamente 123 mg de equivalentes de base libre de migalastat para mejorar la masa ventricular izquierda y/o para mejorar la globotriaosilceramida en podocitos. Reivindicación 1: Un método para reducir el índice de masa ventricular izquierda (LVMi) en un paciente tratado previamente con una terapia de reemplazo enzimático (ERT) que sufre de la enfermedad de Fabry, caracterizado porque dicho método comprende administrar al paciente una formulación que comprende una cantidad eficaz de migalastat o una sal del mismo cada dos días, en donde la cantidad eficaz es de aproximadamente 123 mg de equivalente de base libre (FBE).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/213,920 US9999618B2 (en) | 2007-04-26 | 2016-07-19 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109103A1 true AR109103A1 (es) | 2018-10-31 |
Family
ID=59416847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102027A AR109103A1 (es) | 2016-07-19 | 2017-07-19 | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12070453B2 (es) |
| EP (5) | EP4356911A1 (es) |
| JP (4) | JP6752270B2 (es) |
| KR (3) | KR20240017126A (es) |
| CN (1) | CN109661230A (es) |
| AR (1) | AR109103A1 (es) |
| AU (2) | AU2017298376A1 (es) |
| CA (1) | CA3031249A1 (es) |
| CL (1) | CL2018001677A1 (es) |
| CO (1) | CO2018006358A2 (es) |
| IL (2) | IL313907A (es) |
| MX (2) | MX2018007669A (es) |
| TW (2) | TW201806597A (es) |
| WO (1) | WO2018017721A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007137072A2 (en) | 2006-05-16 | 2007-11-29 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| ES2836121T3 (es) | 2008-02-12 | 2021-06-24 | Amicus Therapeutics Inc | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
| WO2018017721A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| SI3630114T1 (sl) | 2017-05-30 | 2024-03-29 | Amicus Therapeutics, Inc. | Migalastat za zdravljenje bolnikov s fabryevo boleznijo, z ledvično okvaro |
| CA3065298A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| ES2969263T3 (es) * | 2018-02-06 | 2024-05-17 | Amicus Therapeutics Inc | Tratamiento de pacientes con enfermedad de Fabry clásica con migalastat |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| EP4299117A3 (en) * | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| CA3141226A1 (en) * | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| KR20220150902A (ko) * | 2020-02-10 | 2022-11-11 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| KR102471225B1 (ko) | 2021-11-18 | 2022-11-28 | 박기용 | 어플리케이션을 통한 소비자 및 농장 연결 시스템 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990011353A1 (en) | 1989-03-24 | 1990-10-04 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| EP0536402A4 (en) | 1990-06-29 | 1993-05-12 | Nippon Shinyaku Company, Limited | Piperidine derivative |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5900360A (en) | 1996-04-10 | 1999-05-04 | Welch; William J. | Correction of genetic defects using chemical chaperones |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| SI2441467T1 (sl) | 2003-01-31 | 2015-10-30 | The Mount Sinai School Of Medicine Of New York University | Kombinirana terapija za zdravljenje motenj pomanjkanja proteina |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| AU2004289327A1 (en) | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease |
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| KR20080033242A (ko) | 2005-06-08 | 2008-04-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법 |
| US7955262B2 (en) | 2005-07-26 | 2011-06-07 | Syneron Medical Ltd. | Method and apparatus for treatment of skin using RF and ultrasound energies |
| US20100004156A1 (en) | 2005-07-27 | 2010-01-07 | Shalesh Kaushal | Small Compounds That Correct Protein Misfolding and Uses Thereof |
| WO2007137072A2 (en) * | 2006-05-16 | 2007-11-29 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| AU2015230773B2 (en) * | 2006-05-16 | 2017-09-28 | Amicus Therapeutics Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| SI2081904T1 (sl) | 2006-09-22 | 2011-05-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Aripiprazol hemifumarat in postopek za njegovo pripravo |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| ES2836121T3 (es) | 2008-02-12 | 2021-06-24 | Amicus Therapeutics Inc | Método para predecir la respuesta al tratamiento farmacológico con chaperona de enfermedades |
| EP2683382B1 (en) * | 2011-03-11 | 2020-04-22 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| JP2013255488A (ja) | 2012-05-18 | 2013-12-26 | Saitama Medical Univ | 拡張期心不全非ヒトモデル動物及びその製造方法、並びに、拡張期心不全予防乃至症状改善活性を有する物質のスクリーニング方法 |
| WO2018017721A1 (en) * | 2016-07-19 | 2018-01-25 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
-
2017
- 2017-07-19 WO PCT/US2017/042872 patent/WO2018017721A1/en active Application Filing
- 2017-07-19 IL IL313907A patent/IL313907A/en unknown
- 2017-07-19 EP EP23219947.1A patent/EP4356911A1/en active Pending
- 2017-07-19 JP JP2018510380A patent/JP6752270B2/ja active Active
- 2017-07-19 KR KR1020247003290A patent/KR20240017126A/ko active Search and Examination
- 2017-07-19 KR KR1020237013747A patent/KR20230061563A/ko not_active Application Discontinuation
- 2017-07-19 CN CN201780054621.XA patent/CN109661230A/zh active Pending
- 2017-07-19 TW TW106124148A patent/TW201806597A/zh unknown
- 2017-07-19 EP EP24168024.8A patent/EP4378524A3/en active Pending
- 2017-07-19 KR KR1020197004780A patent/KR20190030729A/ko not_active IP Right Cessation
- 2017-07-19 US US16/318,905 patent/US12070453B2/en active Active
- 2017-07-19 EP EP17745612.6A patent/EP3487502A1/en not_active Withdrawn
- 2017-07-19 TW TW112140206A patent/TW202408513A/zh unknown
- 2017-07-19 AU AU2017298376A patent/AU2017298376A1/en not_active Abandoned
- 2017-07-19 MX MX2018007669A patent/MX2018007669A/es unknown
- 2017-07-19 EP EP23219937.2A patent/EP4324521A3/en active Pending
- 2017-07-19 AR ARP170102027A patent/AR109103A1/es unknown
- 2017-07-19 EP EP24168026.3A patent/EP4389213A3/en active Pending
- 2017-07-19 CA CA3031249A patent/CA3031249A1/en active Pending
-
2018
- 2018-06-20 CL CL2018001677A patent/CL2018001677A1/es unknown
- 2018-06-20 CO CONC2018/0006358A patent/CO2018006358A2/es unknown
- 2018-06-20 MX MX2022011334A patent/MX2022011334A/es unknown
-
2019
- 2019-01-17 IL IL264301A patent/IL264301A/en unknown
- 2019-05-22 JP JP2019096045A patent/JP2019178140A/ja not_active Withdrawn
-
2021
- 2021-11-08 JP JP2021181583A patent/JP2022033749A/ja not_active Withdrawn
-
2023
- 2023-05-18 US US18/199,120 patent/US20230321065A1/en active Pending
- 2023-07-20 AU AU2023206175A patent/AU2023206175A1/en active Pending
- 2023-11-13 JP JP2023192778A patent/JP2024026079A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6752270B2 (ja) | 2020-09-09 |
| AU2017298376A1 (en) | 2019-03-07 |
| JP2024026079A (ja) | 2024-02-28 |
| CO2018006358A2 (es) | 2018-11-30 |
| IL313907A (en) | 2024-08-01 |
| US20230321065A1 (en) | 2023-10-12 |
| TW202408513A (zh) | 2024-03-01 |
| CA3031249A1 (en) | 2018-01-25 |
| MX2022011334A (es) | 2022-10-07 |
| US20190183869A1 (en) | 2019-06-20 |
| EP3487502A1 (en) | 2019-05-29 |
| WO2018017721A1 (en) | 2018-01-25 |
| EP4324521A3 (en) | 2024-04-24 |
| KR20190030729A (ko) | 2019-03-22 |
| EP4356911A1 (en) | 2024-04-24 |
| IL264301A (en) | 2019-02-28 |
| MX2018007669A (es) | 2018-09-12 |
| CL2018001677A1 (es) | 2019-02-01 |
| JP2018526368A (ja) | 2018-09-13 |
| JP2022033749A (ja) | 2022-03-02 |
| KR20230061563A (ko) | 2023-05-08 |
| EP4324521A2 (en) | 2024-02-21 |
| EP4389213A2 (en) | 2024-06-26 |
| EP4389213A3 (en) | 2024-08-21 |
| EP4378524A3 (en) | 2024-08-14 |
| JP2019178140A (ja) | 2019-10-17 |
| AU2023206175A1 (en) | 2023-08-10 |
| US12070453B2 (en) | 2024-08-27 |
| KR20240017126A (ko) | 2024-02-06 |
| TW201806597A (zh) | 2018-03-01 |
| CN109661230A (zh) | 2019-04-19 |
| EP4378524A2 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
| Erzin | Fentanyl withdrawal | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті |